fashion -WSS

fashion

author：Wikipedia 2025-08-25 05:57:13 - browse：466

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections
Next article： See how much Covid

Wikipedia

WSS

ASCO: Palliative care found as helpful given virtually as in person

Fauci's latest grilling in Congress: 9 hours, behind closed doors

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Let's speed up science by embracing open access publishing

A preacher's new calling: Diversifying neuroscience research

Wikipedia

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Let's speed up science by embracing open access publishing

Wildfire smoke exposes gaps in outdoor worker protections

Letters to First Opinion on caregivers, digital health, and more

What does generative AI mean for health care? We asked experts

STAT Virtual Event: JPM Recap, Live!

Peter Hotez and the public health issue of online harassment

Profiling embryos to choose those with higher IQs is almost a reality

Guidelines to prevent youth baseball injuries need more muscle

Shifting the focus from loneliness to social health

entertainment

At ASCO, AstraZeneca reports strong data for breast cancer drug

Stories you might have missed in 2023: health, science, medicine

Ascension's ugly legal battle over care for poor patients in Texas

Does Paxlovid work in people vaccinated against Covid

American taxpayers paid $1.8 trillion in health care costs in 2022

FDA early review: GLP

Wikipedia

focus

Wikipedia

leisure time